Analyzing Valneva (NASDAQ:VALN) & Titan Pharmaceuticals (NASDAQ:TTNP)

Valneva (NASDAQ:VALNGet Rating) and Titan Pharmaceuticals (NASDAQ:TTNPGet Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Earnings & Valuation

This table compares Valneva and Titan Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Valneva $411.85 million 2.52 -$86.87 million N/A N/A
Titan Pharmaceuticals $1.53 million 9.36 -$8.78 million N/A N/A

Titan Pharmaceuticals has lower revenue, but higher earnings than Valneva.

Institutional & Insider Ownership

15.8% of Valneva shares are owned by institutional investors. Comparatively, 32.5% of Titan Pharmaceuticals shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 2.7% of Titan Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


This table compares Valneva and Titan Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Valneva N/A N/A N/A
Titan Pharmaceuticals -1,779.72% -183.12% -123.74%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Valneva and Titan Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valneva 0 2 1 0 2.33
Titan Pharmaceuticals 0 1 0 0 2.00

Valneva currently has a consensus price target of $25.00, indicating a potential upside of 66.89%. Given Valneva’s stronger consensus rating and higher probable upside, research analysts clearly believe Valneva is more favorable than Titan Pharmaceuticals.

Volatility & Risk

Valneva has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.


Valneva beats Titan Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

About Valneva

(Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

About Titan Pharmaceuticals

(Get Rating)

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with's FREE daily email newsletter.